Trial Profile
A phase III randomized controlled trial of anastrozole compared to anastrozole plus fulvestrant as adjuvant endocrine therapy for postmenopausal women with estrogen receptor +/- progesterone receptor positive breast cancer
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 08 Dec 2008
Price :
$35
*
At a glance
- Drugs Anastrozole (Primary) ; Fulvestrant (Primary)
- Indications Breast cancer
- Focus Therapeutic Use
- 04 Apr 2007 New trial record.